斯佩西亭

斯佩西亭
法律规范状态
法律规范	美：未列入管制;
识别信息
	IUPAC命名法 methyl (E)-2-[(2S,3S,12bR)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate; ;
CAS号	14382-79-7
PubChem CID	5376107;
ChemSpider	20124314;
UNII	M3NN8Z8ZJW;
ChEMBL	ChEMBL4546925;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID50574160 ;
化学信息
化学式	C23H30N2O4
摩尔质量	398.50 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
熔点	104 °C
	SMILES CC[C@@H]1CN2CCC3=C([C@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC;
	InChI InChI=1S/C23H30N2O4/c1-5-14-12-25-10-9-15-21-18(7-6-8-20(21)28-3)24-22(15)19(25)11-16(14)17(13-27-2)23(26)29-4/h6-8,13-14,16,19,24H,5,9-12H2,1-4H3/b17-13+/t14-,16+,19-/m1/s1; Key:LELBFTMXCIIKKX-MYLQJJOTSA-N;

斯佩西亭（英语：Speciociliatine）^[2]是存在于卡痛树中主要生物碱，其为哥冬树中的另一种主要生物碱帽柱碱（英语：Mitragynine）的立体异构体。在干叶片中含量为0.00156- 2.9%。^[3]^[4]为一种阿片样肽受体配体。

药理作用

已知斯佩西亭是μ-阿片样肽受体（英语：μ-opioid receptor）和κ-阿片样肽受体（英语：κ-opioid receptor）的配体，但其起到激动剂还是竞争拮抗剂作用目前存在争议。^[5]^[6]

在雄性实验大鼠身上测试表明，口服20 mg/kg斯佩西亭后，斯佩西亭的消除半衰期为2.6 - 5小时，绝对生物利用度为20.7%^[7]。

参考文献

^ National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 15560576, Speciociliatine..
^ 苏子仁，赖小平. 汉英、英汉中草药化学成分词汇. 北京: 中国中医药出版社. 2006: 710. ISBN 9787801569103.
^ Sharma, A., Kamble, S. H., León, F., Chear, N. J. ‐Y., King, T. I., Berthold, E. C., Ramanathan, S., McCurdy, C. R., Avery, B. A., Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography−tandem mass spectrometry, Drug Testing and Analysis (Wiley), 2019, 11 (8): 1162–1171, PMC 7927418  , PMID 30997725, doi:10.1002/dta.2604
^ Manwill, P. K., Flores-Bocanegra, L., Khin, M. Raja, H. A.; et al, Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products, Planta Medica (Georg Thieme Verlag KG), 2022, 88 (9/10): 838–857, PMC 9343938  , PMID 35468648, doi:10.1055/a-1795-5876
^ Obeng, S., Kamble, S. H., Reeves, M. E.; et al, Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids, Journal of Medicinal Chemistry (American Chemical Society (ACS)), 2019, 63 (1): 433–439, PMC 7676998  , PMID 31834797, doi:10.1021/acs.jmedchem.9b01465
^ Kruegel, A. C., Gassaway, M. M., Kapoor, A; et al, Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators, Journal of the American Chemical Society (American Chemical Society (ACS)), 2016, 138 (21): 6754–6764, PMC 5189718  , PMID 27192616, doi:10.1021/jacs.6b00360
^ Berthold, E. C., Kamble, S. H., Raju, K. S.; et al, Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method, Journal of Pharmaceutical and Biomedical Analysis (Elsevier BV), 2021, 194: 113778, PMID 33277117, S2CID 227296714, doi:10.1016/j.jpba.2020.113778

[1] National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 15560576, Speciociliatine..

[2] 苏子仁，赖小平. 汉英、英汉中草药化学成分词汇. 北京: 中国中医药出版社. 2006: 710. ISBN 9787801569103.

[:3-3] Sharma, A., Kamble, S. H., León, F., Chear, N. J. ‐Y., King, T. I., Berthold, E. C., Ramanathan, S., McCurdy, C. R., Avery, B. A., Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography−tandem mass spectrometry, Drug Testing and Analysis (Wiley), 2019, 11 (8): 1162–1171, PMC 7927418  , PMID 30997725, doi:10.1002/dta.2604

[:2-4] Manwill, P. K., Flores-Bocanegra, L., Khin, M. Raja, H. A.; et al, Kratom (Mitragyna speciosa) Validation: Quantitative Analysis of Indole and Oxindole Alkaloids Reveals Chemotypes of Plants and Products, Planta Medica (Georg Thieme Verlag KG), 2022, 88 (9/10): 838–857, PMC 9343938  , PMID 35468648, doi:10.1055/a-1795-5876

[:4-5] Obeng, S., Kamble, S. H., Reeves, M. E.; et al, Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids, Journal of Medicinal Chemistry (American Chemical Society (ACS)), 2019, 63 (1): 433–439, PMC 7676998  , PMID 31834797, doi:10.1021/acs.jmedchem.9b01465

[:5-6] Kruegel, A. C., Gassaway, M. M., Kapoor, A; et al, Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators, Journal of the American Chemical Society (American Chemical Society (ACS)), 2016, 138 (21): 6754–6764, PMC 5189718  , PMID 27192616, doi:10.1021/jacs.6b00360

[:6-7] Berthold, E. C., Kamble, S. H., Raju, K. S.; et al, Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method, Journal of Pharmaceutical and Biomedical Analysis (Elsevier BV), 2021, 194: 113778, PMID 33277117, S2CID 227296714, doi:10.1016/j.jpba.2020.113778

[2]

[3]

[4]

[1]

[5]

[6]

[7]

法律规范状态


法律规范	美：未列入管制
识别信息
IUPAC命名法 methyl (E)-2-[(2S,3S,12bR)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
CAS号	14382-79-7
PubChem CID	5376107
ChemSpider	20124314
UNII	M3NN8Z8ZJW
ChEMBL	ChEMBL4546925
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID50574160
化学信息
化学式	C₂₃H₃₀N₂O₄
摩尔质量	398.50 g·mol⁻¹
3D模型（JSmol（英语：JSmol））	交互式图像
熔点	104 °C^[1]
SMILES CC[C@@H]1CN2CCC3=C([C@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC
InChI InChI=1S/C23H30N2O4/c1-5-14-12-25-10-9-15-21-18(7-6-8-20(21)28-3)24-22(15)19(25)11-16(14)17(13-27-2)23(26)29-4/h6-8,13-14,16,19,24H,5,9-12H2,1-4H3/b17-13+/t14-,16+,19-/m1/s1 Key:LELBFTMXCIIKKX-MYLQJJOTSA-N